Equities Analysts Issue Forecasts for RNAC Q2 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Wedbush issued their Q2 2025 earnings estimates for shares of Cartesian Therapeutics in a research note issued to investors on Wednesday, July 9th. Wedbush analyst M. Fan expects that the company will earn ($0.74) per share for the quarter. Wedbush currently has a "Outperform" rating and a $38.00 target price on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share. Wedbush also issued estimates for Cartesian Therapeutics' Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.65) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.18) EPS, FY2028 earnings at ($2.64) EPS and FY2029 earnings at ($2.91) EPS.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.69 million.

A number of other equities research analysts have also recently issued reports on RNAC. Needham & Company LLC cut their price objective on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Cartesian Therapeutics in a research report on Wednesday, April 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.00.

Cartesian Therapeutics Stock Down 2.0%

Shares of Cartesian Therapeutics stock traded down $0.26 during trading on Friday, reaching $13.06. The company's stock had a trading volume of 47,603 shares, compared to its average volume of 87,027. Cartesian Therapeutics has a 52-week low of $8.46 and a 52-week high of $26.50. The company has a market cap of $338.91 million, a price-to-earnings ratio of -0.25 and a beta of 0.36. The firm's 50-day moving average is $10.46 and its two-hundred day moving average is $14.13.

Institutional Investors Weigh In On Cartesian Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Cartesian Therapeutics by 54.4% in the 4th quarter. Bank of America Corp DE now owns 11,690 shares of the company's stock worth $209,000 after purchasing an additional 4,120 shares during the period. Northern Trust Corp lifted its position in Cartesian Therapeutics by 50.6% during the 4th quarter. Northern Trust Corp now owns 95,030 shares of the company's stock valued at $1,702,000 after acquiring an additional 31,915 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Cartesian Therapeutics by 44.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,786 shares of the company's stock valued at $104,000 after acquiring an additional 1,789 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Cartesian Therapeutics by 40.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 26,803 shares of the company's stock valued at $480,000 after acquiring an additional 7,755 shares during the period. Finally, Geode Capital Management LLC lifted its position in Cartesian Therapeutics by 63.0% during the 4th quarter. Geode Capital Management LLC now owns 221,257 shares of the company's stock valued at $3,963,000 after acquiring an additional 85,557 shares during the period. 86.95% of the stock is owned by hedge funds and other institutional investors.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.